Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB)

CAPS Rating: 2 out of 5

Results 1 - 20 of 22 : 1 2 Next »

Recs

0
Member Avatar pchop12316 (58.36) Submitted: 4/19/2016 10:26:44 AM : Underperform Start Price: $1.38 NAVB Score: -1.78

less than impressive

Recs

0
Member Avatar BooDog2 (< 20) Submitted: 5/6/2015 12:12:01 PM : Outperform Start Price: $1.25 NAVB Score: +11.26

$NAVB basing near the $ once again. New management and great potential with their new platform under Goldberg. Gonzalez as the new CEO pushing the marketing potential for Lymphoseek. $2+ short term potential imo.

Recs

0
Member Avatar FlyinBlind (23.20) Submitted: 3/28/2015 9:32:05 AM : Underperform Start Price: $1.68 NAVB Score: +17.54

NAVB will outperform the market over the next 5 years, but due to its burn rate on R&D and G&A, it will go through a number of rounds of financing that will dilute out shareholders. This stock will excel, but there are stocks that are closer to monetizing shareholdeer value

Recs

0
Member Avatar minmartar (< 20) Submitted: 9/19/2014 1:00:18 AM : Outperform Start Price: $1.44 NAVB Score: -6.55

No competition.
Extremely undervalued.

Recs

0
Member Avatar BYUofU (40.63) Submitted: 9/24/2013 1:34:02 PM : Outperform Start Price: $2.83 NAVB Score: -72.33

"old-timers" mapping process...

Recs

0
Member Avatar kwisthoff (< 20) Submitted: 8/20/2013 10:46:08 PM : Outperform Start Price: $3.11 NAVB Score: -80.59

With the recent C-code approval as well as a full quarters worth of lymphoseek profits, this stock is poised for a huge run up. It is already drastically undervalued and with a solid pipeline working its way through fda approval. A 5-6 dollar share price by the new year is completely feasible.

Recs

0
Member Avatar chaimyfromwilli (< 20) Submitted: 8/1/2013 9:04:00 PM : Outperform Start Price: $3.07 NAVB Score: -76.22

Revenue just started to stream

Recs

0
Member Avatar ironjoohyun (< 20) Submitted: 12/6/2012 10:33:24 AM : Outperform Start Price: $2.62 NAVB Score: -93.02

Has the potential to rise a few cents and that is it

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 8:14:51 PM : Outperform Start Price: $4.26 NAVB Score: -118.32

PDUFA coming up

Recs

0
Member Avatar biotechplayer333 (< 20) Submitted: 11/30/2011 7:32:11 AM : Outperform Start Price: $2.34 NAVB Score: -108.11

Lymphoseek clinical data was outstanding, with a spotless safety profile. Current mapping agents have significant drawbacks. The company also has RIGScan CR coming back to clinical trials, and is adding a third drug to their pipeline in Q4 or Q1/2012. This could be an up and coming specialty pharma play.

Recs

1
Member Avatar mkklaren1968 (< 20) Submitted: 10/19/2011 7:01:46 PM : Outperform Start Price: $2.73 NAVB Score: -128.17

As of 10/19/11, Neoprobe's New Drug Application (NDA) for Lymphoseek® (tilmanocept) has been accepted for review by the FDA.

Recs

0
Member Avatar PeterLeyssens (< 20) Submitted: 10/18/2011 4:10:13 PM : Outperform Start Price: $2.69 NAVB Score: -117.30

bet for stock option

Recs

1
Member Avatar BuffettJunior1 (96.11) Submitted: 10/16/2011 7:16:05 PM : Underperform Start Price: $3.02 NAVB Score: +124.71

Extremely overvalued trash stock.

Recs

0
Member Avatar Keekers44 (65.67) Submitted: 9/15/2011 5:32:11 PM : Outperform Start Price: $3.15 NAVB Score: -126.30

I like the recent insider buying.

Recs

0
Member Avatar KimLanners (< 20) Submitted: 8/9/2011 4:50:17 PM : Outperform Start Price: $2.46 NAVB Score: -122.92

biotech

Recs

0
Member Avatar irishma (< 20) Submitted: 7/5/2011 10:32:24 AM : Outperform Start Price: $3.29 NAVB Score: -112.46

they have a great product and another product in development

Recs

3
Member Avatar Cheesus (< 20) Submitted: 5/5/2011 2:38:32 PM : Outperform Start Price: $4.43 NAVB Score: -122.19

Lymphoseek has passed two separate phase 3 trials, showing superiority over the drug (blue dye) currently used to detect cancer. There's 450 million right there if they charge the same price as blue dye, but they will charge more if the FDA does in fact give it to the superior label. Their next drug, which is actually their oldest drug, RigScan CR, has an estimate of 3 Billion. They will use the revenue from Lymphoseek and possibly partner with another company to develop this huge drug.

Recs

1
Member Avatar WebbedFox (< 20) Submitted: 3/30/2011 7:52:02 PM : Outperform Start Price: $4.32 NAVB Score: -123.66

They are on track w/Lymphoseek, a game changer in the diagnosis of cancer.

Recs

0
Member Avatar brewvestor (< 20) Submitted: 2/15/2011 2:29:59 PM : Outperform Start Price: $3.71 NAVB Score: -118.14

1) Lymphoseek has had no safety events
2) Fully funded through the NDA
3) Management now has experience
4) Multiple pre-NDA meetings with FDA
5) Pre-approval negotiated distribution deal in place

Recs

0
Member Avatar reachmygoals1 (< 20) Submitted: 1/29/2011 4:22:45 PM : Outperform Start Price: $2.65 NAVB Score: -109.03

very speculative, can be 10 end of the year if everything goes well.

Results 1 - 20 of 22 : 1 2 Next »

Featured Broker Partners